Indoco Remedies Sells Mumbai Land Parcel for ₹64 Crore
Indoco Remedies Limited sold a plot of land in Mumbai's Mahal Industrial Estate for ₹64 crore on August 27, 2026. The land measures 2,876.08 square meters. The sale is not expected to impact business operations and does not involve related parties.
The sale of land is not material to the company's overall business operations or financial strategy, hence the impact is assessed as low.
The sale of land is a non-operational transaction that does not significantly impact the company's core business or financial performance. It is a routine asset disposal.
Indoco Remedies Limited has executed a Deed of Conveyance on August 27, 2026, for the sale of its plot of land located at Plot No.18/A of Mahal Industrial Estate, Village Mulgaon, Taluka Andheri, District Mumbai Suburban. The land admeasures approximately 2,876.08 square meters built-up area. The sale consideration for this transaction is ₹64,00,00,000 (Rupees Sixty Four Crores Only).
The company has stated that this sale of land will not have any impact on its ongoing business operations. Furthermore, it does not constitute a sale of an undertaking or substantially the whole of the undertaking of the Company as per Section 180(1)(a) of the Companies Act, 2013.
The agreement was entered into with Kalpataru Townships Private Limited. There are no significant terms such as special rights for appointing directors, first right to share subscription, or restrictions on capital structure. The parties involved are not related, and the transaction does not fall within related party transactions. There is no potential conflict of interest arising from this agreement.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.